Purchase Order 75N91019P00131

The National Cancer Institute awarded a delivery order valued at $2.68 million to The Broad Institute, Inc. for DNA whole genome sequencing services supporting new Cancer Genomics Consortium studies. The contract, which commenced September 1, 2020 and was initially scheduled to conclude August 31, 2023, operates under the NCI Genomic Characterization Centers master indefinite delivery contract as a parent vehicle. Performance will be conducted in Cambridge, Massachusetts, with firm fixed-price...

The National Cancer Institute awarded a definitive contract to The Broad Institute, Inc. for cancer genomics cloud pilots on September 29, 2014, with a ceiling value of $12,575,491.50 under cost-no-fee pricing and no set-aside. Place of performance is Cambridge, MA. The contract was ultimately completed on September 28, 2017. A modification incorporated HHSAR 352.232-71 electronic submission of payment requests in full text and provided instructions for transition from OFM submission to IPP.

This federal contract award to The Broad Institute, Inc. (doing business as Broad Institute of MIT and Harvard) provides DNA characterization services to support the genomic research initiatives of several National Cancer Institute (NCI) programs, including the Cancer Genome Characterization Center, Clinical Proteomic Tumor Analysis Consortium, and Division of Cancer Epidemiology and Genetics. The $19,570,872.26 firm-fixed-price delivery order was issued under the NCI Genomic Characterization...

<p>The National Cancer Institute awarded a purchase order to Innomics Inc. for $24,449.00 on September 22, 2020, for eukaryotic transcriptome resequencing. Work is performed in Cambridge, Massachusetts, with completion targeted for November 30, 2020. The order is a firm fixed-price acquisition for commercial genomic sequencing and bioinformatics services.</p>

<p>The National Cancer Institute issued a $3,598.76 delivery order to Illumina, Inc. on January 24, 2018, for materials for project, with final completion scheduled for February 18, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced firm fixed-price with no set-aside designation.</p>

<p>The National Cancer Institute issued a $17,792.10 delivery order to Illumina, Inc. on January 13, 2020, for reagents and consumables.</p> <p>Place of performance is Bethesda, MD 20892. Ultimate completion date is February 12, 2020. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

<p>The National Cancer Institute issued a $5,217.50 delivery order to Illumina, Inc. on February 8, 2018, with an ultimate completion date of March 10, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $20,283.34 on April 24, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland. The order is set to complete by July 19, 2020.</p>